Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin in advanced solid tumors
NCT05126433Phase 2Terminated
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Mar 2022
- Primary completion
- Dec 2023
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of lurbinectedin in urothelial carcinoma (UC), neuroendocrine carcinoma (NEC), solid tumor, sponsored by Jazz Pharmaceuticals plc. Started Mar 2022; status: terminated.
02
Drugs
lurbinectedin
03
Conditions
urothelial carcinoma (UC)neuroendocrine carcinoma (NEC)solid tumor
Beyond the preview
Go deeper on NCT05126433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05126433.